There is an urgent need to identify new agents or combination therapies to benefit patients whose tumors have developed resistance to current RET inhibitors. Currently, the true extent of RET-dependent (resistance mutations in the RET gene) versus RET-independent mechanisms of resistance is unknown. Dr. Heymach’s team will study mechanisms and biomarkers of RET-independent drug resistance and test different drug combinations to overcome RET inhibitor resistance.
Grant title (if any)
Hamoui Foundation / LUNGevity Lung Cancer Research Award
John Heymach, MD, PhD
The University of Texas MD Anderson Cancer Center